MorphoSys AG and Constellation Pharmaceuticals, Inc., announced that they have entered into a definitive agreement whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion. The transaction has been unanimously approved by the management board (Vorstand) and the supervisory board (Aufsichtsrat) of MorphoSys, as well as the Board of Directors of Constellation and is expected to close in the third quarter of 2021.
ContraVir Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has...
Rafael Pharmaceuticals, Inc. announced the initiation of a phase III multicenter, open-label, randomized pivotal trial (AVENGER 500) to evaluate the...
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial pneumonia with an unpredictable course.
PDS Biotechnology Corporation announced that it has completed the enrollment of the lead-in safety cohort of its VERSATILE-002 Phase II study evaluating the efficacy and safety of the combination of PDS 0101, a clinical stage immunotherapy to treat cancers caused by infection with the human papillomavirus (HPV), and Keytruda (pembrolizumab), a checkpoint inhibitor (CPI)
Two post-hoc pooled analyses of the Phase III INPULSIS trials have been presented that further demonstrate the efficacy of Ofev...
Rafael Pharmaceuticals, Inc. announced that the AVENGER 500 Phase iII clinical trial evaluating the efficacy and safety of CPI-613 (devimistat) in combination with modified FOLFIRINOX (mFFX) as a first-line therapy in patients with metastatic adenocarcinoma of the pancreas did not meet its primary endpoint of overall survival.
PDS Biotechnology announced an upcoming poster presentation of preliminary data from its ongoing Phase II VERSATILE-002 clinical trial at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7, 2022 in Chicago and online.
Cardiac shock is the leading cause of death in patients with acute myocardial infarction.
Novartis announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based, global biopharmaceutical company developing innovative medicines in oncology.